Hologic has positioned itself at the forefront of the $70.92 billion point-of-care diagnostics market projected by 2032, leveraging its Clarity™ AI platform to deliver MRI-precision breast and skeletal imaging at the bedside. With the CMS ACCESS Model launching in July 2026 to incentivize outcome-based care, Hologic’s software-defined imaging solutions are expected to capture a growing share of facility reimbursements by reducing scan times by up to 40% and cutting capital equipment overhead by nearly 25%, according to internal forecasts. As a key partner alongside VentriPoint Diagnostics, Butterfly Network and Hyperfine, Hologic reported a 15% year-over-year increase in shipments of portable imaging devices during fiscal 2025, underscoring the accelerating adoption of AI-powered diagnostics in outpatient and rural clinics.

In January 2026, Hologic launched ‘Ultimate Defense,’ a nationwide initiative to reverse a multi-year decline in routine cervical cancer screening rates. The campaign aims to increase combined Pap plus HPV test coverage by 20% over the next two years, focusing on underserved demographics where screening rates have fallen below 65%. Hologic is partnering with over 1,200 OB/GYN practices and community health centers, deploying customized educational materials and mobile screening units, with the goal of reaching an additional 500,000 women by the end of fiscal 2026. Early pilot data show a 12% uptick in first-time screening appointments within six months of program launch.

Hologic plans to release first-quarter fiscal 2026 results on January 29, after market close, but will forgo its customary earnings call and refrain from issuing full-year guidance due to its pending acquisition by Blackstone and TPG. This transaction, announced in October 2025 and valued at approximately $11 billion, remains on track for completion in mid-calendar 2026, subject to customary regulatory approvals. Investors will be watching closely for reported revenue trends in the Women’s Health division—which generated more than 60% of total sales in fiscal 2025—and any commentary on integration plans as Hologic transitions from a public to a privately held company.